These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6600010)

  • 1. Circadian mesor of recumbent pulse--cost-effective predictor of doxorubicin-induced congestive heart failure.
    Hrushesky WJ; Vukelich M
    Chronobiol Int; 1984; 1(1):59-66. PubMed ID: 6600010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-hour mean pulse. Simple predictor of doxorubicin-induced cardiac damage.
    Hrushesky WJ; Vukelich M; Steiner B; Dell I; Mukai K
    Am J Med; 1984 Sep; 77(3):399-406. PubMed ID: 6475981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
    Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
    Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
    Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
    J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
    Speyer JL; Green MD; Zeleniuch-Jacquotte A; Wernz JC; Rey M; Sanger J; Kramer E; Ferrans V; Hochster H; Meyers M
    J Clin Oncol; 1992 Jan; 10(1):117-27. PubMed ID: 1727913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac sequelae of doxorubicin and paclitaxel as induction chemotherapy prior to high-dose chemotherapy and peripheral blood progenitor cell transplantation in women with high-risk primary or metastatic breast cancer.
    Klein JL; Rey PM; Dansey RD; Karanes C; Du W; Abella E; Cassells L; Hamm C; Peters WP; Baynes RD
    Bone Marrow Transplant; 2000 May; 25(10):1047-52. PubMed ID: 10828864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer.
    Gianni L; Dombernowsky P; Sledge G; Martin M; Amadori D; Arbuck SG; Ravdin P; Brown M; Messina M; Tuck D; Weil C; Winograd B
    Ann Oncol; 2001 Aug; 12(8):1067-73. PubMed ID: 11583187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
    Villani F; Meazza R; Materazzo C
    Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
    Batist G; Ramakrishnan G; Rao CS; Chandrasekharan A; Gutheil J; Guthrie T; Shah P; Khojasteh A; Nair MK; Hoelzer K; Tkaczuk K; Park YC; Lee LW
    J Clin Oncol; 2001 Mar; 19(5):1444-54. PubMed ID: 11230490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
    Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.
    Swain SM; Whaley FS; Ewer MS
    Cancer; 2003 Jun; 97(11):2869-79. PubMed ID: 12767102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
    Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
    N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-induced congestive heart failure in adults.
    Haq MM; Legha SS; Choksi J; Hortobagyi GN; Benjamin RS; Ewer M; Ali M
    Cancer; 1985 Sep; 56(6):1361-5. PubMed ID: 4027874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
    Safra T; Muggia F; Jeffers S; Tsao-Wei DD; Groshen S; Lyass O; Henderson R; Berry G; Gabizon A
    Ann Oncol; 2000 Aug; 11(8):1029-33. PubMed ID: 11038041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.